Completed NA INTERVENTIONAL 2-arm NCT01499147

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Sponsor: University of Illinois at Chicago

Conditions Acute Leukemia Acute Myeloid Leukemia Aplastic Anemia Chronic Myelogenous Leukemia Hodgkin's Disease Lymphocytic Leukemia Malignant Lymphoma Multiple Myeloma Myelofibrosis Myeloproliferative Disorder Polycythemia Vera

Interventions ATG fludarabine/ melphalan fludarabine/busulfan

Updated 10 times since 2017 Last updated: Oct 9, 2018 Started: Feb 29, 2000 Primary completion: May 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01499147, this NA trial focuses on Acute Leukemia and Acute Myeloid Leukemia and remains completed. Sponsored by University of Illinois at Chicago, it has been updated 10 times since 2000, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 5 earlier versions

Dec 2018 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Dec 2018 [monthly]

Completed NA
Jul 2017 — Jun 2018 [monthly]

Completed NA
Feb 2017 — Jul 2017 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Illinois at Chicago

Data source: University of Illinois at Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States